

Drug Delivery



ISSN: 1071-7544 (Print) 1521-0464 (Online) Journal homepage: informahealthcare.com/journals/idrd20

Microneedles for drug delivery: trends and progress

Karmen Cheung & Diganta B. Das

To cite this article: Karmen Cheung & Diganta B. Das (2016) Microneedles for drug delivery: trends and progress, Drug Delivery, 23:7, 2338-2354, DOI: 10.3109/10717544.2014.986309

To link to this article: https://doi.org/10.3109/10717544.2014.986309



Published online: 23 Dec 2014.



Submit your article to this journal 🗗

Article views: 11470



View related articles



View Crossmark data 🗹



Citing articles: 60 View citing articles 🖸

http://informahealthcare.com/drd ISSN: 1071-7544 (print), 1521-0464 (electronic)

Drug Deliv, 2016; 23(7): 2338–2354 © 2014 Informa Healthcare USA, Inc. DOI: 10.3109/10717544.2014.986309

informa healthcare

REVIEW ARTICLE

Microneedles for drug delivery: trends and progress

Karmen Cheung and Diganta B. Das

Department of Chemical Engineering, Loughborough University, Loughborough, Leicestershire, UK

Abstract

In recent years, there has been a surge in the research and development of microneedles (MNs), a transdermal delivery system that combines the technology of transdermal patches and hypodermic needles. The needles are in the hundreds of micron length range and therefore allow relatively little or no pain. For example, biodegradable MNs have been researched in the literature and have several advantages compared with solid or hollow MNs, as they produce non-sharp waste and can be designed to allow rapid or slow release of drugs. However, they also pose a disadvantage as successful insertion into the stratum corneum layer of the skin relies on sufficient mechanical strength of the biodegradable material. This review looks at the various technologies developed in MN research and shows the rapidly growing numbers of research papers and patent publications since the first invention of MNs (using time series statistical analysis). This provides the research and industry communities a valuable synopsis of the trends and progress being made in this field.

Introduction

Drug delivery (DD) has historically been pivotal in ensuring drugs can be administered in a manner that leads to therapeutic efficacy. Methods of DD, such as oral ingestion or hypodermic injections, are considered to be the most common forms of drug administration (Davis et al., 2004; Escobar-Chávez et al., 2011). However, they possess several limitations, e.g. pain associated with hypodermic injections due to the long needles piercing nerve endings and absorption and metabolism issues associated with oral administration that lead to variability in bioavailability and also side effects from metabolites (Guy, 1996). These disadvantages have led to the development of alternative DD methods. An encouraging alternative to the traditional methods is DD directly through the skin surface, i.e. transdermal drug delivery (TDD). Commercially available transdermal patches (TDP) now exist, which provide controlled release of medicines to patients in a minimally invasive manner. However, large molecules cannot passively permeate through the stratum corneum (SC), thereby, limiting the number of such transdermal drug products available to patients. Problems can also arise from the TDP's peeling off due to the long periods for which they are required to be applied. Several approaches have been researched to overcome the problems with TDPs and allow delivery of compounds like proteins and DNA (Benson & Namjoshi, 2008; Daugimont et al., 2010; Kalluri & Banga, 2011; Garland et al., 2012; Chandrasekhar et al.,

Keywords

Autoregressive integrated moving average, microneedle, time series analysis

History

Received 19 September 2014 Revised 6 November 2014 Accepted 6 November 2014

2013; Katsumi et al., 2014), so that they can permeate through the skin.

DD routes

An overview of DD routes are described in this section briefly to provide some perspective on this important area of research, in particular, to provide an understanding of why there is a need to develop new technologies and where microneedles (MNs) fit in to the picture. Numerous forms of DD routes are currently being used, which include, oral administration (gastric, colonic, enteric, etc.), hypodermic injections (e.g. intra-venous, intra-muscular, intra-cranial, sub-cutaneous injections, etc.), inhalation (pulmonary) and TDD (skin appendages) (Sullivan et al., 2008; Li et al., 2013). Oral administration and hypodermic injections are the most common delivery methods with approximately 80% of drugs administered orally. However, several difficulties associated with oral dosage forms exist, e.g. pH changes within the body causing degradation to drugs, enzymatic activity, variable transit time, side effects and first-pass metabolism (Sullivan et al., 2008). The main disadvantages of using hypodermic injections is the resultant infection, pain caused during application, patient fear, anxiety and patient incompetence.

A good alternative that can overcome such problems is transdermal delivery of drugs (TDD), which can resolve issues such as by-passing first-pass metabolism (thus eliminating harmful metabolites whilst increasing bioavailability) and patient compliance. The method operates by transporting drug molecules from the surface of the skin into the body. It has been continuously developed ever since the first transdermal product was approved in 1979 in the United States to treat motion sickness (Prausnitz & Langer, 2008).

Address for correspondence: Diganta B. Das, Department of Chemical Engineering, Loughborough University, Loughborough LE11 3TU, Leicestershire, UK. Email: D.B.Das@lboro.ac.uk

Transdermal delivery includes the applications of gels, creams, ointments and more recently TDP (Margetts & Sawyer, 2007; Behin et al., 2013; Nalesniak et al., 2013). One transdermally delivered drug that is commonly used is nicotine (Ravi et al., 2011), first developed in 1984 by Rose et al. (1984) to help smokers give up smoking. The drug was Food and Drug Administration (FDA) approved in 1991 and has been on the market since 1992 (Margetts & Sawyer, 2007).

However, there are disadvantages associated with TDPs, for example, the prevention of large molecules from bypassing the SC, the outermost layer of the skin, which is the ratelimiting barrier (Sinha & Kaur, 2000; Garland et al., 2011; Han & Das, 2013; Ling & Chen, 2013). TDPs are applicable for molecules that are traditionally smaller than 500 Da (Benson, 2005). Methods that have been employed to solve the short comings of both TDPs and hypodermic injections are ultrasound (Yamashita et al., 1996; Han & Das, 2013; Nayak et al., in press), MNs, iontophoresis (Langkjær, et al., 1998), electroporation, chemical enhancers and others (Yamashita et al., 1996; Yang et al., 2011). These techniques can overcome the protective SC barrier as they allow the passage of large molecular compounds such as proteins and DNA (Benson & Namjoshi, 2008; Daugimont et al., 2010; Li et al., 2013; Zhang et al., 2014a,b). MN technology, in particular, has grown over the past 15 years and can permit drugs to bypass the SC layer by the insertion of micron sized needles that create micro channels through the SC (McAllister et al., 1998; Mitragotri, 2013; Pierre & Rossetti, 2014). The MNs are small enough in length to avoid touching nerve endings of a patient, thereby, causing little or no pain (Henry et al., 1998). Furthermore, MN technology has shown to be more advantageous in comparison to the other TDD techniques (Prausnitz et al., 2004), such as the ability to deliver large molecular molecules that are larger than 500 Da (Benson, 2005) and the versatility in the application to allow solid or liquid formulations to be developed for disease specific applications.

There are numerous journal papers that have reviewed different types of DD technologies (Wu et al., 2012; Chandrasekhar et al., 2013; Fazil et al., 2013; Kamboj et al., 2013; Tuan-Mahmood et al., 2013; Zhang et al., 2013; Ita, 2014; Nalwa, 2014; Wolff, 2014) and specific drug deliveries, such as insulin (Martanto et al., 2004; Zahn et al., 2005; Ito et al., 2006; Khanna et al., 2008; Taylor & Sahota, 2013; Bronger, 2014; Natayan, 2014). A number of review papers have also discussed specific technologies, e.g. various methods to fabricate MNs, or the devices that are currently being used or are likely to be used in clinical trials (Giri Nandagopal et al., 2014; Jain et al., 2014). Indeed, one can safely assume that the most significant aspects of MNs research have been discussed in review or research papers. However, one issue that is obvious is that there is little attempt to quantify the trend in the progress of MN technology. In other words, it is not clear how slow or fast the rate of progress is for the development the MNs-based methods. It is also not clear from the existing literature what method one could use to quantify the trends and, if the trend could be quantified reliably given that the MNs based research is still relatively new as compared to most other TDD methods. This review paper will look into assessing these gaps in the literature by using a time series analysis of the journal papers found in Scopus, using a time series analysis tool namely, autoregressive integrated moving average (ARIMA) model (also known as univariate Box-Jenkins analysis) to look at the future trend patterns in the number of publications based on several key word searches. The information was gathered by conducting searches in the home page document search function only, as opposed to searching "microneedle" and then searching within the results, the second key work (e.g. "solid"). Quantifying and predicting past and future trends are important to determine the market values of these products as there is a growing interest to produce MN's to a commercial quality and scale. It is therefore important to view what is the current trend in literature, similar to how a start-up a business would require market research. We assume that the number of publications is the key indicator of how well the MN technology has developed and use the keywords "microneedle", "solid microneedle", "hollow microneedle" and "dissolvable microneedle" to determine the number of publications corresponding to each keywords (using Scopus). The program IBM SPSS Statistics version 21 was used to produce the time series analysis tool and analyze the data from Scopus. The ARIMA model was created by omitting 2014 data as it is currently incomplete, therefore the analysis will give an indication of the trend till 2013 (Pankratz, 1983). For the completeness of this article, we discuss other relevant issues as well as follows.

Why MNs?

TDPs have been delivering a variety of drugs since the early 1980's such as testosterone, nicotine, selegiline and clonidine (Prausnitz et al., 2004). Although there are several commercially available TDPs, they are limited by the SC, which includes overcoming the mass transfer resistance (Margetts & Sawyer, 2007). TDPs administer drugs via passive diffusion as illustrated in Figure 1(A) (Shah et al., 2011). There are two mechanisms for the storage of drugs on TDPs. A drug is either stored in a reservoir or incorporated into the transdermal patch fabric, whereby it is transported across the skin via a concentration gradient (Margetts & Sawyer, 2007). Although these methods have shown to be applicable for a variety of drug formulations, they are still limited by the drug molecules that can permeate through the SC barrier. As mentioned earlier, MNs have been proposed as an alternative delivery method to TDPs and hypodermic syringes as they have shown to overcome the various short comings previously outlined. Indeed, it has been illustrated by Benson & Namjoshi (2008) and many other researchers (Li et al., 2011b; Shah et al., 2011; Liebl & Kloth, 2012) that MN research is a promising field of research to be pursued more extensively as it can be used to overcome the skin's natural defensive barrier, the SC, in both adults and children. The rate of release of the drug depends upon the controlling membrane of the TDP (Osborne et al., 2013), and therefore ensuring a consistent drug release profile can be uncertain.

MNs have been made possible to make due to the technological advances that have occurred in the past 20 years. Since the independent invention of the hypodermic

Figure 1. Cross section through human skin (A) intracellular, (B) hair follicles and sweat glands, (C) direct pathway through the SC and, (D) depicts the micron sized holes that can be created by MNs upon the skin (modified from Shah et al. (2011)).



needle in the mid 1850s (Krapp & Longe, 1998) by Wood & Pravaz, hypodermic needles (Lawrence, 2002), or syringes, have been the most common form to administer biotherapeutics (Sullivan et al., 2008). MN use has the advantage of simple patient administration of drugs with minimal invasiveness to the patients (Donnelly & Woolfson, 2014; Donnelly et al., 2014). The MNs would only permeate the SC and not the nerve receptors, consequently, the patients would feel little or no pain (Henry et al., 1998), though longer MNs can also be used where deeper delivery of the drug is desired. Therefore, the development of MNs is important as it has the potential to overcome numerous disadvantages posed by the traditional DD systems (Gratieri et al., 2013).

Current applications of MNs include the delivery of macromolecules such as vaccines, proteins and peptides including insulin for diabetics. One such example for vaccines delivery is reported by Edmonston-Zagreb for measles vaccination (Nordquist et al., 2007; Herwadkar & Banga, 2012; Kis et al., 2012; Singh et al., 2012; Edens et al., 2013; Koutsonanos et al., 2013; Ling & Chen, 2013; Cai et al., 2014; Gill et al., 2014). Vaccinations have the capacity to be delivered using MN patches, which require the patient to have no specialized training or the need for cold/refrigerated storage; this in turn can reduce the spread of diseases (Prausnitz et al., 2009; Edens et al., 2013). Therefore, the successful delivery of patch biotherapeutics is a desirable drug administration method. Furthermore, there are initial challenges to overcome, such as the low permeability of skin, which can limit the permeation of drugs. With MN, this challenge can be overcome.

Skin

We discuss skin and its properties briefly in this section because the skin barrier needs to be understood and overcome before MNs can be designed and applied successfully. Human skin is the largest organ in the human anatomy with an approximate surface area of $20\,000\,\mathrm{cm}^2$ on an average human male, which spans the entire external surface of the body (Gray, 2005), in which its main function is to contain all the internal organs, protect them against foreign organisms and bacteria and act as a passive barrier. Some of the skin's other functions include the regulation of internal body temperature, insulation, resistance against foreign bacteria and to provide protection to the internal organs (Gray, 2008). The surface area of the skin constantly changes depending on age, weight loss and gain (Seidenari et al., 1994; Petrofsky et al., 2008), height and sex of a human being (Lee & Hwang, 2002). It is also a receptive organ to thermal heat and pain. The skin comprises of several layers of which the main layers consist of the epidermis, dermis and subcutaneous tissue (Gray, 2008; see Figure 1). The figure illustrates the SC, a non-living layer, which provides the first barrier to foreign bodies and DD. Below the SC layer is the epidermis-containing living tissue with no blood vessels. Below this is where drugs are taken up by capillaries in the dermis layer (Shah et al., 2011). As evident in the figure, there are several pathways in which molecules can permeate through the skin, which can be categorized into two routes, the appendageal and transepidermal routes. The appendageal route includes the movement through hair follicles and sweat glands (Figure 1B) and offers a high permeability to ions and large polar molecules (Benson, 2005). The surface area is considerably small, and therefore, the exploration of passing drugs using this form of route is considered of little importance. The transepidermal route is a direct pathway through the SC (Figure 1C). This can occur via an intracellular (Figure 1A) or transcellular route (Figure 1C) (Benson, 2005).

With the varying skin surface areas, there is also a dramatic difference in the skin thickness within the human body, which is important in the absorption of therapeutics (Kamboj et al., 2013). Therefore, analysis into skin thickness is important, as outlined in a study of skin thickness of Korean males and females conducted by Lee & Hwang (2002). In the study, they found that the thickness of skin is vastly variable due to a number of factors. These include the race, sex and age of a person and also on different areas of the body. It has also been shown that aging and diabetes have an effect on skin thickness (Petrofsky et al., 2008). In particular, it was found that subcutaneous fat thickness in different body regions was thinner in aging skin and in diabetic patients. A reduction in the skin thickness of the hand was also observed for diabetic patients. Therefore, consideration of skin thickness would need to be examined when choosing an active site for TDD in general (Kamboj et al., 2013) and MNs in specific.

Mechanical properties of skin

Understanding the mechanical properties of skin and detailed knowledge on various skin layers (Smalls et al., 2006) are important as the insertion of needles into the skin would alter the skins mechanical response to all skin layers (Roxhed et al., 2007). Knowledge of the properties of skin would help better understand the effect MNs have and therefore help determine what needs to be overcome when designing or inserting a MN. Skin is a viscoelastic material in which research has been conducted to ascertain what factors can influence skin properties. These include the site at which a material can be located, the age of the patient, the thickness of the skin, orientation, etc. (Cua et al., 1990; Karande et al., 2006; Smalls et al., 2006; Boettcher et al., 2013). It is a complex organ that continuously changes as we age (Cua et al., 1990). A property of skin that has been studied is the skin's ability to fold upon itself, such as wrinkling (Magnenat-Thalmann et al., 2002). Smalls et al. (2006) investigated the body's biomechanical skin properties, which showed a significant difference in elasticity, stiffness and laxity for the right side in comparison to the left side of the body. This was possibly the result of 90% of subjects being right handed, which illustrated that an increase in muscle tone can also have an effect on the biomechanical skin properties. Cua et al. (1990) concluded that the biomechanical properties of skin decreased with increasing age, which may be due to natural degeneration as we get older. SC thickness on human forearm, palm, cheek and lower leg were also studied to determine by using two non-invasive measuring techniques namely, confocal Raman spectroscopy and confocal laser scanning microscopy, to measure SC thickness which were then compared to the thickness in literature data. It was found that it was possible to accurately measure the SC thickness with both techniques (Bohling et al., 2013).

Increasing permeability of skin

The use of MN as a DD system is an important development as the potential to allow a wider scope of molecules to be transdermally delivered through the skin is greatly increased (Dhamech et al., 2010; Gittard et al., 2010; Milewski et al., 2010; Singh et al., 2010). The amount of drug that is delivered can also be increased. However, an understanding of the permeability of skin would need to be established in order to determine how to increase drug content (Lanke et al., 2009; Prausnitz et al., 2009; Subedi et al., 2010). It is important to look at skin thickness when investigating increasing permeability of skin, as increasing skin permeability is important for TDD. The invention of the MN can overcome this factor as the needles bypass the SC layer, which is the rate dependent layer and can allow large molecular weight proteins to pass into the blood stream (Prausnitz, 2004). A well-known method to quantify the drug release through skin is the use of Franz diffusion cells and therefore have been used in literature extensively to calculate the permeability of skin (Henry et al., 1998; Park et al., 2005; Singh & Banga, 2013).

There have been multiple papers outlining various methods conducted to analyze different techniques to increase the permeability of skin. They can be categorized into chemicaland physical-enhancing techniques, some of which include, thermal ablation, sonophoresis and electroporation (Guy, 1996; Sinha & Kaur, 2000; Mitragotri & Kost, 2004; Daugimont et al., 2010; Han & Das, 2013; Mitragotri, 2013). Sinha & Kaur (2000) stated that an individual enhancement technique cannot possess all the desired properties to facilitate the transport of drugs transdermally. However, the data published by Prausnitz et al. (2004) illustrate that the use of MNs is a promising technique as it possessed many of the required properties for the delivery of drug therapeutics. Figure 1(D) depicts the micron-sized holes that can be created by MNs upon the skin.

There are several physical methods that have been used in conjunction with MN technology to increase skin permeation (Hilt & Peppas, 2005; Trommer & Neubert, 2006; Nava-Arzaluz et al., 2012). One such example is the use of sonophoresis with MNs. It is a technique that allows molecules to permeate through the barrier of the skin more readily as ultrasonic waves create micro-vibrations on the skin (Mitragotri & Kost, 2004). Monomeric insulin analogues were studied to investigate the rate of iontophoresis transport on mice skin (Langkjær et al., 1998). The study showed clinically relevant results for insulin regulation.

Several review papers have been published on different types of enhancement techniques (Al-Saidan, 2004; Benson, 2005; Arora et al., 2008; Tanner & Marks, 2008; Banga, 2009; Yadav et al., 2011; Milewski & Mitra, 2012; Mitragotri, 2012; Ukawala Ravikumar & Vasava, 2012; Nalesniak et al., 2013), which outline various uses of chemical enhancers like N-methyl-2-pyrrolidone, a pyrrolidone (Sinha & Kaur, 2000) used in the application of insulin, ibuprofen and flurbiprofen. The applications of these techniques for increasing skin permeability would be useful when delivering drugs transdermally. Table 1 lists some examples of enhanced protein/ peptide delivery systems across the skin and the outcome of the experiments.

Trends in MN DD method

MNs can be considered to be a micron scale hybrid between TDPs and hypodermic syringes to overcome limitations that are associated with the individual application. They are small arrays of needles that are generally less than 1 mm in length (Aggarwal et al., 2009; Bariya et al., 2012; Desale et al., 2012; Shikida, 2012). There are multiple MN designs that have been created over the past decade. They can be categorized into two types, solid or hollow MNs (Bariya et al., 2011). The materials that have been used to fabricate them range from metal (Choi et al., 2013), glass, silicon (Wei-Ze et al., 2010) and biodegradable polymers (polydimethylsiloxane) (Chu & Prausnitz, 2011; Bediz et al., 2013) and silk fibroin (Tsioris et al., 2012). More recently, the use of fish scales have also been investigated (Olatunji et al., 2014). Ideally, the materials used would be pharmacologically inert, non-toxic, compatible with pharmaceutical ingredients, etc. (Sinha & Kaur, 2000). Metals traditionally used for MN fabrication consist of stainless steel, nickel coated in gold, titanium, platinum and palladium (Martanto et al., 2004; Wang et al., 2006; Mansoor et al., 2013). Although numerous journal papers have been published on the use of silicon as a primary substituent of MN

Table 1. Examples of enhanced protein/peptide delivery to and across the skin.

Protein/peptide	Delivery method	Main outcome	References
Bovine serum albumin	Polymeric microneedles	All drug released in six hours for <i>in vitro</i> permeation studies	Kochhar et al., 2012
Bovine serum albumin	Microneedles, ultrasound	BSA permeability of 1 μm/s is achieved with a 1.5-mm height microneedle and 15 W ultrasound output	Han & Das, 2013
Bovine insulin and bovine serum albumin Microneedles coupled with iontophoresis MN design containing 361 MNs/cm ² of drug permeation in six hours on neonatal porcine skin <i>in vitro</i>		Garland et al., 2012	
Botulinum toxin A	Stainless steel microneedles	Efficient diffusion through the dermis	Torrisi et al., 2013
Hepatitis B surface antigen	Elastic liposomes	Systemic and mucosal antibody response elicited in mice	Benson & Namjoshi, 2008
Hepatitis B virus DNA vaccine	Jet propulsion (Powderject)	Application to healthy human volunteers resulted in both humoral- and cell-mediated immune responses	Benson & Namjoshi, 2008
Insulin Insulin-loaded dissolvable Dissolved in five minutes in rats to relative pharmacological availal and gelatin and relative bioavailability of 9		Dissolved in five minutes in rats to relative pharmacological availability and relative bioavailability of 92%	Ling & Chen, 2013
Influenza subunit vaccine	Microneedles delivery	Application to intramuscular injection in guinea pigs. Hemagglutinin concen- trations as high as 20 mg/ml	Kommareddy et al., 2013
Measles	Microneedles delivery	Measles was able to be coated and dried onto MN. Vaccine delivery into rats was comparable to using hypodermic needles, which gave similar antibody tilters	Edens et al., 2013

formulation, the material itself has yet to be FDA approved (Park et al., 2005).

MNs provide a direct pathway for drugs to access the viable dermis, allowing for a painless DD that by-passes the SC (Benson & Namjoshi, 2008). They also differ in shape, ranging from square, circular, flat tipped, sharp tipped, etc. (Henry et al., 1998; Park et al., 2005; Gupta et al., 2009; Swain et al., 2011; Kommareddy et al., 2013; Mansoor et al., 2013; Torrisi et al., 2013; Pierre & Rossetti, 2014). There has been a lot of research conducted on MNs for the delivery and monitoring of various drugs such as glucose control for diabetics (Ito et al., 2006; Nordquist et al., 2007; Ainslie & Desai, 2008; El-Laboudi et al., 2013; Taylor & Sahota, 2013; Ita, 2014), Alzheimer's disease (Wei-Ze et al., 2010), anticancer (Fang et al., 2008) and other conditions (Ezan, 2013). Vaccines have also been a prominent research field with numerous studies developed to allow dose sparing effects (Edens et al., 2013; Norman et al., 2014; van der Maaden et al., 2014). There have been multiple studies conducted to optimize the delivery of drugs using MNs with numerous methods to fabricate them.

Park et al. (2005) used biodegradable polymer MNs with sharp tips to overcome problems associated with safety and disposal. They found that the use of biodegradable MNs increased skin permeability by three fold, which increase the delivery of drugs transdermally. Gupta et al. (2009) used hollow MNs for bolus delivery of lispro insulin in comparison to catheter infusion. They found that MNs inserted 1 mm into human skin showed rapid insulin absorption with no pain observed from the volunteers in comparison to catheter infusion (Gupta et al., 2009).

A method to fabricate MNs is important, as desirable attributes would be to have a simplistic fabrication method that is low cost and reproducible. This would be advantageous when mass producing MNs for industrial application (Indermun et al., 2014). However, the delivery of drugs using MNs can be conducted in four different ways. These can be known as "poke and patch", "coat and poke", formulating the API (active pharmaceutical ingredient) with a biodegradable polymeric MN (Cheung et al., 2014; Nayak et al., 2014) or by channeling the drug through the channels of a hollow MN (Prausnitz, 2004). Multiple MN designs have been fabricated that facilitate the piercing of the SC allowing the permeation of drugs (Wei-Ze et al., 2010).

The rate of the development in MN research has increased significantly since the first papers have been published. A time series analysis forecast based on ARIMA model has been applied to the 1228 papers that have been found using the database Scopus with the search term "microneedle". ARIMA is used to extrapolate future trends in data based on previous data sets. The forecast is shown in Figure 2. Trends will also be determined for specific MN types in the forthcoming sections in the paper.

A "single series" of ARIMA forecast is based only on the past values of the variables being forecasted, the variables in this case are the number of journal publications (NOJP). It tells us how an observation on the NOJP is statistically related to past observation on the same variable. All forecasts are extrapolations and therefore produce projections based on past patterns or relationships into the future. The model is used for short-term forecasting in this paper, which relies upon the data collected from recent pasts as opposed to distant past.

Figure 2 represents the time series analysis in graphical form. The observed and fitted data show a good match, which give the confidence that the ARIMA model is reliable in predicting the trend. The trend shows that there are some fluctuations in the number of publications in various years. However, overall, there is a considerable increase in the number of MN publications in the past 10 years. The ARIMA

Figure 2. Forecasted, fitted and observed results on the trend of publications on microneedles using the keyword "microneedle".



fit shows a good prediction of the trend (beyond 2015) when the total number of future MN publications are forecasted. The figure shows the yearly observations of the number of publications published since 1982–2013 (1228 total publications) and forecasted to 2016. The predicted NOJP for 2016 are shown to be approximately 300, which is a significant increase from the 218 papers found in Scopus for year 2013.

Number Publications

Hollow MNs

Hollow MNs are traditionally used to allow liquid formulations through the SC and act like micron scale syringes. They have an added advantage as they can permit the administration of a larger drug dose compared to solid MNs (Benson & Namjoshi, 2008). They have also been shown to allow an increase in drug infusion rate due the fact that pressure can be applied across the length of the MN with administration. Ahmad et al. (2009) have shown the in situ assembly of hollow liquid filled polymeric MNs for DD. Hollow metal MN arrays have been fabricated to allow the continuous administration of drugs. Micromachining methods have been used to make machine moulds from polyethylene terephthalate using UV lasers (Griss & Stemme, 2003; Davis et al., 2005; Roxhed et al., 2007). However, hollow MNs are still considered to be mechanically weaker involving complicated manufacturing processes and more complex to use than solid MNs as solid MNs are considered to be more robust (Escobar-Chávez et al., 2011). There have been other advancements in recent research to allow manufacture of any height, pitch and lumen-lumen spacing of the MNs (Lee & Jung, 2012; Mansoor et al., 2013). Griss & Stemme (2003) fabricated out-of-plane hollow MNs to overcome the short comings of blockages caused by hollow MNs. The design consists of an opening on the shaft of the MN as opposed to the tip for the delivery of drugs using a microfluidic liquid transfer. These were made by a deep reactive-ion etching method.

Roxhed et al. (2007) developed a method of fabricating MNs that combines a controlled flow of drugs using out of plane MNs. Nordquist et al. (2007) conducted a study using hollow MNs fabricated from metal, which improved the Griss

and Stemme design. MNs of length 400 μm and pitch 500 μm were produced.

ARIMA model has been applied to the 167 journal papers that have been found in the journal data base Scopus with the search term "hollow microneedle" (Figure 3). It is obvious that the fitted and the observed data do not match well which is due to the small number of publications per year. This suggests that while the total numbers of publications relating to hollow MNs are increasing, the trend (e.g. the number of publications in different years) cannot be reliably predicted. Nevertheless, the ARIMA model has been applied to predict the future trend in the journal papers. It shows that the number of publications on hollow MNs would decline, which seems to support a hypothesis that research groups are potentially leading away from hollow MNs use due to the complications in manufacture and their brittle nature.

Solid MNs

Solid MNs are more robust than hollow MNs and have a stronger mechanical strength (Escobar-Chávez et al., 2011). MNs can produce micro pores in skin, which bypasses the SC layer, and allow drugs to permeate to the viable epidermis (Wei-Ze et al., 2010). There have been a number of methods and materials used to fabricate solid MNs (Jain et al., 2011; Khan et al., 2014), some of which are represented in Table 2.

The first reported case of solid MNs in literature was in the study of gene therapy (Hashmi et al., 1995). However, Henry et al. (1998) was the first to demonstrate the feasibility of delivering drugs transdermally. They designed conical shaped MNs, 150 μ m in length and <1 μ m tip diameter (Figure 4A). This allowed easy piercing of the MN into skin and produced a four order of magnitude increase in skin permeability. In this study, a deep reactive ion etching microfabrication technique was used. Although the fabrication method yielded reproducible fabrication of MNs, the insertion of MNs into human cadaver skin left a small proportion of the needles bent at the tip 5–10 μ m. Khan et al. (2014) prepared coated MNs utilizing a process named ''electrohydrodynamic atomization'' to produce pharmaceutical coatings on a single MN

Figure 3. Forecasted, fitted and observed results on the trend of publications on hollow microneedle using the keyword "hollow microneedle".



patch for the purpose of applying personalized medicine. Martanto et al. (2004) fabricated solid metal MNs by cutting metal sheets with an infrared laser. The MNs were then manually bent into the 90° angle. The MNs were in an array containing 105 MNs, 1000 μ m in length and a cross section at base of 50 μ m × 200 μ m. The MN was tapered to a sharp tip (angle 20°) (Illustrated in Figure 4B). This method of fabrication was shown to be laborious and used a number of strong acids, which could pose problems when disposing of such chemicals. The application of this MN into hairless rats also required an external high velocity applicator to successfully insert the MN into the skin. Although the MNs used to elucidate the transdermal delivery of insulin produced successful data in reducing glucose levels by up to 80%, the fabrication method would not be considered a simple process.

The fabrication of biodegradable and biocompatible polymers was proposed by Park et al. (2005) to address the issues associated with cost-effective fabrication materials and problems associated with MN fabrication materials, such as metal, a sharp hazardous waste and silicon, which has yet to be FDA approved (Park et al., 2005). The material was considered to be a safer alternative as it is mechanically strong and relatively inexpensive.

As listed in Table 2, silicon has been widely researched when developing MNs. Polydimethylsiloxane was used by Chu & Prausnitz (2011) to show the material combined the mechanical strength that metal MNs (Figure 5) can provide and the useful properties of silicon drug based arrow head (Figure 6). They showed that the production of a blunt metal shaft with a detachable drug encapsulated arrow head on the end could provide drug to the viable epidermis within seconds to porcine and human cadaver skin.

There have been several types of polymer MNs that have been created to overcome the non-biocompatible and nonbiodegradable properties of metal and silicon MNs (Park et al., 2005; Hong et al., 2013; Lee et al., 2013; Nayak & Das, 2013). The biodegradable MNs were fabricated using a lithographic approach. Dissolving MNs were fabricated by Ito et al. (2006) in which insulin was mixed at room temperature to dextrin and deionized water and dried in a desiccator after thread was attached. Three different mixtures of insulin were made and tested on rats, which illustrated the uses of dissolving MNs to successfully deliver the drug precutaneously. Table 2 illustrates a general overview of the transdermal MN methods used to administer drugs and vaccines. For example, the table shows that dissolving insulinbased MNs were made with starch and gelatin (Ling & Chen, 2013) for a five-minute dissolution time when inserted into the skin. It was shown that $600 \,\mu$ m height and $300 \,\mu$ m base MN retained pharmacological activity in the starch/gelatin matrix.

ARIMA model has been applied to the 112 journal papers that have been found using the journal data base Scopus with the search term "solid microneedle". Although the trend has declined in the observed data for 2013–2014, the results show that there would be an increase in the amount of solid MN papers in the future.

It has been reported in the literature that breakage of MNs is considered to be minimal as long as the insertion of the MNs is gentle. It was also stated that metal MNs are more robust than other materials used to manufacture MNs and that biodegradable needles are safer (Benson & Namjoshi, 2008).

Although the use of silicon as a primary material in some MN fabrication methods is favored, it is hindered by the fact that the material is currently not approved by the FDA (Park et al., 2005). Research has been conducted on the use of large sharp MNs but little has been carried out on the effect of short blunt MNs on increasing the permeability of skin. What little research has been conducted shows increasing permeability to longer sharper MNs. This shows that there is a potential for developing a new MN, which is blunt and short in length.

Solid MNs have been shown in the literature to have a typical length of $150 \,\mu\text{m}$ - $350 \,\mu\text{m}$. However, studies into the fabrication of super short MNs with a length of $70-80 \,\mu\text{m}$ were conducted by Wei-Ze et al. who have shown that supershort MNs are capable of successfully delivering galanthamine, a drug used for Alzheimer's. The study compared the use of sharp super-short MNs against blunt super-short MNs and longer sharp needles of $1500 \,\mu\text{m}$ as shown in Figure 7. The super short MNs were made using wet etching of silicon using acupuncture needles backed onto the minipore of a basement. The study found that as more pressure was applied

Table 2. Methods of fa	bricating solid MNs.					,0050,
Methods	Materials	Dimensions (µm)	Advantages	Disadvantages	References	
Separable dissolving arrow heads	 (Polydimethylsiloxane (PDMS) Sylgard 184,), Metal shaft Water-soluble excipients – PVP, sucrose PLGA 	600 μm-long PVP/PVA arrowhead capped onto a metal shaft with an exposed length of 600 μm and a 100 μm overlap.	 Rapid (1–5 s)/painless drug/vaccines delivery PDMS: inert/non-toxic/non flammable Rapid (1–5 s)/painless drug/vaccines delivery, convenient/safe/potential self-administration, can allow controlled release of active ingredient Advantage over coated needlesclimination of bio-hazardous waste, allow self-administration Does not require extended patch wearing even for long duration of drug releases. PDMS: inert PDMS: non-toxic 	 Difficult insertion into skin as requires wider needle geometry (non-blunt shaft) Non reusable Fibrotic reaction 	Chu & Prausnitz, 2011; Backovic et al., 2007	
Dissolving	• Mixture insulin, water, dextrin	Basal diameter: 3.24 ± 0.16 and 0.55 ± 0.03 mm	 Bio-compatible 	Produce bio hazardous sharp waste	Ito et al., 2006	
Pyramidal dissolving polymer	 Polyvinyl alcohol (PVA), Polyvinylpyrrolidone (PVP) A = pyramidal MN B = extended pyramidal MNs C = pedestal MNs 	Base width × base depth × needle height: A: 300 µm× 300 µm× 600 µm. B: 300 µm× 300 µm× 900 µm. C: 340 µm× 340 µm× 900 µm)	 Ability to increase drug capacity and localize to the MN tip Allowed a deeper insertion Higher increase of drug to be dissolved 	 Large tipped Produce bio hazardous sharp waste 	Chu et al., 2010	11111
Deep reactive ion etching	ChromiumSilicon wafers	120×10^{-41} and 120μ m length, <1 μ m tip diameter	Mechanically strong	 Reusability questionably Top 5–10 μm of MN damaged for a faw samulas 	Henry et al., 1998	onecun
Dissolving. fabri- cated by a draw- ing technique to	• Maltose	1200 µm length 60 µm tip diameter	• Requires no moulds, therefore no sharp waste	Complicated process	Lee et al., 2011	is joi unit
Cutting metal using infrared laser, manually bending the MN structure, electropolished	• Metal	1000 μ m length, 50 μ m × 200 μ m cross section at base, tapered to a sharp tip (angle 20°), 106 array	• A short MN insertion time was better than a longer insertion time to facilitate drug permeation	 Insertion of large array was difficult by hand without external device Strong acids used 	Martanto et al., 2004	success 2

(continued)

	References	on Martin et al., 2012	Edens et al., 2013	na Ling & Chen, 2013 for
	Disadvantages	 MN patch needles to be left of the skin for potentially over 20 min 	Produce bio hazardous sharp waste	• Time to reach minimum plast glucose level slightly longer i MN than for subcutaneous injection of insulin
2. Continued	Advantages	 Fast dissolution of drug into skin Use of simple sugars to create biodegradable MNs 	 Dose of measles vaccine is small, therefore the dimensions of the MN are sufficient to allow coating and delivery of the vaccine Needles long enough for rat dorsal thickness (700 µm-1000 µm) penetration Cost effective manufacturing 	 Rapid dissolution of five min- utes was achieved Pharmacological activity retain in the starch/gelatin
TAUC	Dimensions (µm)	200 µm base 20 µm tip 300 µm height	750 μm height 200 μm × 50 μm at the base. Single row of five MNs	600 μm height 300 μm base 5 μm tip
	Materials	 Sugar glass MN: Trehalose/mannitol (50:50 w/w) Trehalose dehydrate/sucrose (75:25w/w) Trehalose/sucrose (75:25 w/w) Trehalose/sucrose (50:50 w/w) 2% (w.w) methylene blue 	• Stainless steel	 Starch/gelatin (1:1 ratio) PDMS mould
	Methods	Silicon master mould to make PDMS inverse mould	Stainless steel MN produced by chemical etching	Dissolving MN

to insert the MNs, the permeation of the drug increased (Wei-Ze et al., 2010). There is currently little literature regarding the feasibility of blunt short MNs against sharp long MNs. Based on the findings of Wei-Ze et al., there could potentially be a gap in the literature to pursue further the implications of using the is method of DD on various drugs and see the effect the MN has on skin permeability. This shows a promising fabrication method for the delivery of drugs transdermally. Table 3 lists the main parameters of super short MNs in the study conducted by (Wei-Ze et al., 2010). However, considering the various fabrication methods, there seems to be a need for a simpler robust technique that requires minimal cost, as the process is economically viable and relatively robust.

ARIMA model has been applied to the 16 journal papers that have been published in the journal database Scopus with the search term "dissolvable microneedle".

There is little data on the publication of dissolvable MNs. However, there is a growing trend in the use of dissolvable MNs, which is apparent due to the benefits of incorporating active drug directly to the manufacture of MNs. Although the ARIMA forecast in Figure 8 seems to fit this trend due to the lack of observations the forecast would not be a useful estimate of the mean as there would essentially only be one observation per mean. Therefore, this forecast would not be an ideal assumption of the predicted NOJP for 2016.

MNs patents

T

MNs have become more prominent within the past decade. The use of MNs as a method for the transdermal delivery of drugs has become a more appealing technique as it overcomes many disadvantages, such as discomfort and pain that can be caused by hypodermic needles or the non-bioavailability that oral dosage forms provide. Therefore, it is important to look at patents that have been filed within the last decade to correlate the trends of MNs (Rizwan et al., 2009; Sachdeva & Banga, 2011; Singh et al., 2011). Table 4 lists a summary of patents that have been taken out on materials to fabricate MNs. Table 5 lists some example patents on the methods of MN fabrication. Table 6 lists patents on chemicals used for MN transdermal delivery system. Figure 9 illustrates the number of patents taken for various MN designs. It can be seen that there is a considerable amount of MN patens taken out on hollow MNs. This may be due to the fact that hollow MNs have the advantage of delivering a higher dosage in comparison to other methods (Bariya et al., 2011).

Transdermal delivery of drugs is a continually growing field with an abundant of journal papers being published each year on MN technology and an increasing number of patents filed. Therefore, an increase in development for more commercially viable MN products would need to be conducted.

Conclusion

Oral administration and hypodermic syringes are the most commonly used delivery methods in today's society. However, they pose several disadvantages such as painful side effects of using hypodermic syringes or the problem associated with oral administration such as drug

Т

- 1



Figure 4. SEM images of various microneedles: (A) solid conical shaped microneedle (Henry et al., 1998), (B) solid microneedle next to a 27-gauge syringe (Martanto et al., 2004).



Figure 5. Forecasted, fitted and observed results on the trend of publications on solid microneedle using the keyword "solid microneedles".



Figure 6. Images of an arrow head microneedle (Chu & Prausnitz, 2011).

bioequivalence (Guy, 1996). TDPs pose numerous advantages as an alternative method as they provide controlled release of medicine to the patient in a minimally invasive manner. However, they cannot permeate large molecules to pass the SC (the top layer of skin), thereby limiting the medical application to patients. MNs have been proposed to overcome this limitation and provide the transdermal delivery of large molecular weight proteins such as shown by Benson & Namjoshi (2008). Various MN designs and fabrication methods have been explored in the literature ranging from the fabrication of, hollow, solid, dissolvable, sharp and short MNs. The MNs can be made from polymers, metals, glass and silk. There is a gap in the literature that has not been explored - the commercial viability of MNs - for an industrially viable product to be manufactured on an industrial scale. Various techniques discussed in this literature review have shown laborious techniques and involve the use

results on the trend of publications on

"dissolvable microneedle".



Figure 7. Super-short microneedles. SEM images of (A) a single sharp tipped super-short microneedle, (B) a single flat tipped super-short microneedle and (C) an angled view of a flat tipped super-short microneedle array (Wei-Ze et al., 2010).

Table 3. Parameters of super short MNs (Wei-Ze et al., 2010).

Method	Materials	Dimensions (µm)	Advantages	Disadvantages
Sharp tipped super short microneedles	 Microneedle: Silicon with 30% potassium hydroxide Patch: Backing: polyethylene Adhesive: polyisobutylene 	75	 Strong material which does not break with insertion forces exceeding 8 N Reusable 	 Permeability of drug is lower compared to flat tipped micro- needle Skin folding shown upon inser- tion of needle compared with flat-tipped microneedle
Flat tipped super short microneedles	 Microneedle: silicon with 30% potassium hydroxide Patch: Backing: polyethylene Adhesive: polyisobutylene 	80	 Increase permeability in skin compared to sharp tipped microneedle Decreases skin barrier function No skin folding shown upon insertion of needle compared to sharp tipped microneedle Strong material, which does not break with insertion forces exceeding 8 N Reusable 	N/A



of non-FDA-approved excipients such as silicon. There is a growing trend in the amount of publications surrounding MN technology. With the increase in the use of MN for commercial scale products, the upward trend in number of publications is unlikely to change in the next decade, due to continuous advances in technology.

The use of time series analysis allows the extrapolation of trends in data to predict the number of journal papers published. This can occur provided the number of data sets (observations) is sufficient to produce a good estimate. In the case of MNs, solid and hollow, this was possible. However this was not sufficient for dissolvable MNs.

Table 4. Example patents on microneedles technology.

Patent number	Date of filing	Applicant	Key invention	Country	References
US 2010042050	16 April 2007	Nemaura Pharma Ltd, USA	Applicator for microneedles.	USA, European, Japan, China, India	Chowdhury, 2010
WO 2011016230	4 August 2010	Medrx Co., Ltd., Japan	Provided is a microneedle device which protects microneedles, has an easily portable shape, is free from such problems as breakage of fine needles in the step of puncturing the skin with the microneedles, and ensures appropriate skin puncture to administer a drug.	Japan	Kobayashi & Hamamoto, 2011
WO 2011084951, US 20110172645	4 January 2011, 8 January 2010	Ratio, Inc., USA	Microneedle configured to facilitate delivery of the drug to the subject. The microneedle includes a tip portion and is moveable from an inactive position to an activated position.	USA	Moga et al., 2011
WO 2011014514	27 July 2010	3 M Innovative Properties Company, USA	This disclosure relates to apparatus, assemblies, com- binations and methods for infusing fluids by hollow microneedles.	USA	Gonzalez et al., 2011
CA 2696810 JP 2011078618 WO 2011043086 AU 2010201434 KR 2011067009 EP 2343102 A1	15 January 2010	Bioserentach Co. Ltd., Japan	Microneedle sheets are pro- duced by injecting a needle raw material into a stamper formed with a concavity in a base material.	Japan	Honda et al., 2011
WO 2013096026	12 December 2012	3 M Innovative Properties Company, USA	Assembly of a microneedle adhesive patch. The assem- bly can include a backing and an adhesive and a matrix coupled to the backing	USA	Cantor & Stockholm,2013
WO 2013066262	2 November 2011	Singapore	Invention relates to plastic microneedle strips that are used in TDD for increasing the DD rate through the skin.	Spain	Lim et al., 2013

Table 5. Example patents on methods of microneedle fabrication.

Patent number	Date of filing	Applicant	Key invention	Country	References
EP 2289843	31 August 2009	University College Cork-National University of Ireland, Cork, Ireland.	The invention relates to a method of fabricating a microneedle device of the type comprising an array microneedles on a flexible polymer support layer.	European	Cork University Patent EP 2289843
JP 2011083387	14 October 2009	Kyushu Institute of Technology, Japan; Nichiban Co., Ltd.	Manufactured. by (1) perform- ing Bosch process to a Si wafer to form a Si micro- needle having a tapered tip and a columnar part with the same diameter or a decreas- ing diameter in the longitu- dinal direction, etching the tip with an etching solution and/or a reactive radical.	Japan	Akiyoshi, 2012
CN 102000020	17 November 2010	Beijing Pharmaceutical Research Institute, Henan Lingrui Pharmaceutical Co., Ltd., People Republic of China;	The title polymer (molecular weight: 1000–1000 000) is selected from poly(<i>p</i> -dioxa- none) or <i>p</i> -dioxanone	China	Huizhen et al., 2011

Patent number	Date of filing	Applicant	Key invention	Country	References
		Beijing Lingrui Hi-tech Co., Ltd.	containing copolymer (containing <i>p</i> -dioxanone 10–100 wt.%), such as poly(<i>p</i> -dioxanone-lactide), poly(<i>p</i> -dioxanone-glyco- lide), etc.		
CN 103263727	22 May 2013	Tsinghua University, People Republic of China.	A metallic microneedle array, including substrate and a metal sheet fixed on the surface of the substrate.	China	Yue & Wang, 2013
US 20130030374 A1	11 October 2012	Toppan Printing Co., Ltd.	Microneedle including forming a plurality of first linear grooves on a substrate in parallel to one another along a first direction using grinding and forming a plurality of second linear grooves on the substrate in parallel to one another in a second direction intersecting the first direction using grinding.	USA	Sugimura et al., 2013
CN 103181887	30 December 2011	Shanghai No.7 People's Hospital, People Republic of China.	Invention relates to triamcino- lone acetonide biodegrad- able maltose microneedle array which contains (1) triamcinolone acetonide or its pharmaceutically accept- able salt and (2) maltose or its hydrate, wherein the length of microneedle is $800-1500 \mu\text{m}$, the diam- eter of the microneedle is $100-300 \mu\text{m}$ and array d. is 9–100 needles/cm ² .	China	Zhang & Wu, 2013

Table 6. Patents on chemicals used for microneedle transdermal delivery system.

Patent number	Date of filing	Applicant	Key invention	Country	References
GB2472778A	17 August 2009	PANGAEA LAB LTD	Microneedle roller.	Great Britain	Saacs & Cobbledick, 2011
WO 2011026144 or S 20110052694	31 August 2009	AllTranz Inc., USA	DD system for pharma- active ingredients (e.g. cannabidiol and prodrugs of cannabidiol).	USA	Stinchcomb et al., 2011
US 20110118560, US 20110118656, US 20110117150, US 20110118652, US 20110118696, US 20110118653, US 20110118697, US 20110118698, US 20110118652 US 20110118656	13 November 2009, 19 February 2010, 9 March 2010	Searete LLC, USA	Provides one or more medicines to mam- malian subject.	USA	Eckhoff et al., 2011
CN 101991846	17 November 2010	Chifeng Boen Pharmaceutical Co., Ltd., People Republic of China	The invention relates to inactivated vaccine for immunoprophy- laxis of bovine mastitis caused by <i>Escherichia coli</i> and its preparation method.	China	Li et al., 2011a

Patent number	Date of filing	Applicant	Key invention	Country	References
US 20130171722	3 January 2012	City University of Hong Kong, Hong Kong	Injection of a substance into a subject includ- ing elongate non- hollow micro-nano- needles for delivering bioactive substance including drug and gene molecules such as plasmid DNA, siRNA, miRNA and shRNA.	USA	Chen & Zhang, 2013



Figure 9. Division of patents filed based on type of MNs (Bariya et al., 2011).

Declaration of interest

The authors declare no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

This work was partly supported by Loughborough University, UK and EPSRC, UK.

References

- Aggarwal G, Garg A, Dhawan S. (2009). Transdermal drug delivery: evolving technologies and expanding opportunities. Indian J Pharm Educ Res 43:251–9.
- Ahmad Z, Stride E, Edirisinghe M. (2009). Novel preparation of transdermal drug-delivery patches and functional wound healing materials. J Drug Target 17:724–9.
- Ainslie KM, Desai TA. (2008). Microfabricated implants for applications in therapeutic delivery, tissue engineering, and biosensing. Lab Chip 8:1864–78.
- Akiyoshi B. Biocompatible microneedle, manufacture thereof, and sheet having the microneedle. Kitakyushu-shi Patent JP 2011083387, 18 April 2012.
- Al-Saidan SM. (2004). Transdermal self-permeation enhancement of ibuprofen. J Control Release 100:199–209.
- Arora A, Prausnitz MR, Mitragotri S. (2008). Micro-scale devices for transdermal drug delivery. Int J Pharm 364:227–36.
- Backovic A, Wolfram D, Del-Frari B, et al. (2007). Simultaneous analysis of multiple serum protiens adhering to the surface of medical grade polydimethylsiloxane elastomers. J Immunol Methods 328: 118–27.
- Banga AK. (2009). Microporation applications for enhancing drug delivery. Expert Opin Drug Deliv 6:343–54.
- Bariya SH, Gohel MC, Mehta TA, Sharma OP. (2011). Microneedles: an emerging transdermal drug delivery system. J Pharm Pharmacol 64: 11–29.

- Bariya SH, Gohel MC, Mehta TA, Sharma OP. (2012). Microneedles: an emerging transdermal drug delivery system. J Pharm Pharmacol 64: 11–29.
- Bediz B, Korkmaz E, Khilwani R, et al. (2013). Dissolvable microneedle arrays for intradermal delivery of biologics: fabrication and application. Pharm Res 31:117–35.
- Behin SR, Punitha IS, Saju F. (2013). Development of matrix dispersion transdermal therapeutic system containing glipizide. Der Pharmacia Lettre 5:278–86.
- Benson HA. (2005). Transdermal drug delivery: penetration enhancement techniques. Current drug delivery 2:23–33.
- Benson HAE, Namjoshi S. (2008). Proteins and peptides: strategies for delivery to and across the skin. J Pharm Sci 97:3591–610.
- Bohling A, Bielfeldt S, Himmelmann A, et al. (2013). Comparison of the stratum corneum thickness measured in vivo with confocal Raman spectroscopy and confocal reflectance microscopy. Skin Res Technol 20:50–7.
- Boettcher B, Stahlhofer KJ, Mattle V, et al. (2013). Ultrasonographic assessment of skin thickness in patients with PCOS a case-control study. Gynecol Endocrinol 29:380–3.
- Bronger C. (2014). Insulin pen needles and adherance. Aus J Pharm 95: 68–71.
- Cai Y, Xu M, Yuan M, et al. (2014). Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes. Int J Nanomed 9: 3527–38.
- Cantor AS, Stockholm AJ. Transdermal adhesive patch assembly with removable microneedle array and method of using same. St Paul Patent WO 2013096026, 27 June 2013.
- Chandrasekhar S, Iyer LK, Panchal JP, et al. (2013). Microarrays and microneedle arrays for delivery of peptides, proteins, vaccines and other applications. Exp Opin Drug Deliv 10:1155–70.
- Chen X, Zhang W. Method and apparatus for delivery of bioactive molecules to cells. Hong Kong Patent US 20130171722, 4 July 2013.
- Cheung K, Han T, Das DB. (2014). Effect of force of microneedle insertion on the permeability of insulin in skin. J Diabetes Sci Technol 8:444–52.
- Choi HJ, Bondy BJ, Yoo DG, et al. (2013). Stability of whole inactivated influenza virus vaccine during coating onto metal microneedles. J Control Release 166:159–71.
- Chowdhury DFH. Microneedle transdermal delivery device. Loughborough Patent US 2010042050, 18 February 2010.
- Chu LY, Choi S-O, Prausnitz MR. (2010). Fabrication of dissolving polymer microneedles for controlled. J Pharm Sci 99:4228–38.
- Chu LY, Prausnitz MR. (2011). Separable arrowhead microneedles. J Control Release 149:242–9.
- Cork University Patent (2011). A microneedle device and method for the fabrication thereof. EP 2289843 (http://www.google.com/patents/ EP2289843A1?cl=en).
- Cua AB, Wilhelm KP, Maibach HI. (1990). Elastic properties of human skin: relation to age, sex, and anatomical region. Arch Dermatol Res 282:283–8.
- Daugimont L, Baron N, Vandermeulen G, et al. (2010). Hollow microneedle arrays for intradermal drug delivery and DNA electroporation. J Memb Biol 236:117–25.

- Davis SP, Landis BJ, Adams ZH, et al. (2004). Insertion of microneedles into skin: measurement and prediction of insertion force and needle fracture force. J Biomech 37:1155–63.
- Davis SP, Martanto W, Allen MG, Prausnitz MR. (2005). Hollow metal microneedles for insulin delivery to diabetic rats. Trans Biomed Eng 52:909–15.
- Desale RS, Wagh KS, Akarte AM, et al. (2012). Microneedle technology for advanced drug delivery: a review. Int J PharmTech Res 4:181–9.
- Dhamech DL, Rajendra VB, Rathi VB, et al. (2010). Physical approaches to penetration enhancement. Int J Health Res 3:57–70.
- Donnelly RF, Mooney K, Caffarel-Salvador E, et al. (2014). Microneedle-mediated minimally invasive patient monitoring. Ther Drug Monit 36:10–17.
- Donnelly RF, Woolfson AD. (2014). Patient safety and beyond: what should we expect from microneedle arrays in the transdermal delivery arena? Therapeutic Deliv 5:653–62.
- Eckhoff PA, Hyde RA, Ishikawa MY, et al. Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject. Bellevue Patent US 20110118560, US 20110118656, US 20110117150, US 20110118652, US 20110118696, US 20110118653, US 20110118697, US 20110118698, US 20110118652, US 20110118656, 19 May 2011.
- El-Laboudi A, Oliver NS, Cass A, Johnston D. (2013). Use of microneedle array devices for continuous glucose monitoring: a review. Diabetes Technol Ther 15:101–15.
- Edens C, Collins ML, Ayers J, et al. (2013). Measles vaccination using a microneedle patch. Vaccine 31:3403–9.
- Escobar-Chávez JJ., Bonilla-Martínez D, Villegas-González MA, et al. (2011). Microneedles: a valuable physical enhancer to increase transdermal drug delivery. J Clin Pharmacol 51:964–77.
- Ezan E. (2013). Pharmacokinetic studies of protein drugs: past, present and future. Adv Drug Deliv Rev 65:1065–73.
- Fang JY, Liu PF, Huang CM. (2008). Decreasing systemic toxicity via transdermal delivery of anticancer drugs. Curr Drug Metab 9: 592–7.
- Fazil M, Ali A, Baboota S, et al. (2013). Exploring drug delivery systems for treating osteoporosis. Exp Opin Drug Deliv 10:1123–36.
- Gill HS, Kang S-M, Quan F-S, Compans RW. (2014). Cutaneous immunization: an evolving paradigm in influenza vaccines. Exp Opin Drug Deliv 11:615–27.
- Gratieri T, Alberti I, Lapteva M, Kalia YN. (2013). Next generation intra- and transdermal therapeutic systems: using non- and minimallyinvasive technologies to increase drug delivery into and across the skin. Eur J Pharm Sci 50:609–22.
- Garland MJ, Caffarel-Salvador E, Migalska K, et al. (2012). Dissolving polymeric microneedle arrays for electrically assisted transdermal. J Control Release 159:52–9.
- Garland MJ, Migalska K, Mazlelaa T, et al. (2011). Microneedle arrays as medical devices for enhanced transdermal drug delivery. Exp Rev Med Devices 8:459–82.
- Giri Nandagopal MS, Antony R, Rangabhashiyam S, Sreekumar N. (2014). Overview of microneedle system: a third generation transdermal drug delivery approach. Microsystem Technol 20: 1249–72.
- Gittard SD, Ovsianikov A, Chichkov BN, et al. (2010). Two-photon polymerization of microneedles for transdermal drug delivery. Expert Opin Drug Deliv 7:513–33.
- Gonzalez BA, Burton SA, Hu J, et al. Hollow microneedle arrays. St Paul Patent WO 2011014514, 3 February 2011.
- Gray H. (2005). Gray's anatomy, 39th ed. Spain: Elsevier.
- Gray H. (2008). Gray's anatomy. 40th ed. Spain: Elsevier Limited.
- Griss P, Stemme G. (2003). Side-opened out-of-plane microneedles for microfluidic transdermal liquid transfer. IEEE J Microelectromech Syst 12:296–301.
- Gupta J, Felner EI, Prausnitz MR. (2009). Minimally invasive insulin delivery in subjects with type 1 diabetes using hollow microneedles. Diabetes Technol Ther 11:329–37.
- Guy RH. (1996). Current status and future prospects of trandermal drug delivery. Pharm Res 13:1765–9.
- Han T., Das DB. (2013). Permeability enhancement for transdermal delivery of large molecule using low-frequency sonophoresis combined with microneedles. J Pharm Sci 102:3614–22.
- Hashmi S, Ling P, Hashmi G, et al. (1995). Genetic transformation of nematodes using arrays of micromechanical piercing structures. Biotechniques 19:766–70.

- Henry S, McAllister DV, Allen MG, Prausnitz MR. (1998). Microfabricated microneedles: a novel approach to transdermal drug delivery. J Pharm Sci 87:922–5.
- Herwadkar A, Banga AK. (2012). Peptide and protein transdermal drug delivery. Drug Discov Today Technol 9:147–54.
- Hilt JZ, Peppas NA. (2005). Microfabricated drug delivery devices. Int J Pharm 206:15–23.
- Honda K, Motoi M, Takada K. Method for producing stamper for microneedle. Kyoto Patent CA 2696810, JP 2011078618, WO 2011043086, AU 2010201434, KR 2011067009, EP 2343102 A1, 10 February 2011.
- Hong X, Wei L, Wu F, et al. (2013). Dissolving and biodegradable microneedle technologies for transdermal sustained delivery of drug and vaccine. Drug Des Dev Ther 7:945–52.
- Huizhen Z, Huibin W, WZhang X, Eizheng J. Degradable polymer-based microneedle patch and its preparation method. Beijing Patent CN 102000020, 6 April 2011.
- Ita KB. (2014). Transdermal drug delivery: progress and challenges. J Drug Deliv Sci Technol 24:245–50.
- Indermun S, Luttge R, Choonara YE, et al. (2014). Current advances in the fabrication of microneedles for transdermal delivery. J Control Release 185:130–8.
- Ito Y, Hagiwara E, Saeki A, et al. (2006). Feasibility of microneedles for percutaneous absorption of insulin. Eur J Pharm Sci 29:82–8.
- Jain A, Jain P, Kurmi J, et al. (2014). Novel strategies for effective transdermal drug delivery: a review. Crit Rev Ther Drug Carrier Syst 31:219–72.
- Jain D, Jain V, Singh R. (2011). Novel antigen delivery technologies: a review. Drug Deliv Transl Res 1:103–12.
- Kalluri H, Banga AK. (2011). Transdermal delivery of proteins. Am Ass Pharm Sci 12:431–41.
- Kamboj S, Jhawat V, Saini V, Bala S. (2013). Recent advances in permeation enhancement techniques for transdermal drug delivery systems: a review. Curr Drug Ther 8:181–8.
- Karande PK, Jain A, Mitragotri S. (2006). Relationships between skin's electrical impedance and permeability in the presence of chemical enhancers. J Control Release 110:307–13.
- Katsumi H, Quan YS, Kamiyam F, et al. (2014). Development of a novel transdermal delivery system of peptide and protein drugs using microneedle arrays. Yakugaku Zasshi 134:63–7.
- Khan H, Mehta P, Msallam H, et al. (2014). Smart microneedle coatings for controlled delivery and biomedical analysis. J Drug Target 22: 790–5.
- Khanna P, Strom JA, Bhansali S. (2008). Microneedle-based automated therapy for diabetes mellitus. J Diabetes Sci Technol 2:1122–9.
- Kobayashi K, Hamamoto H. Applicator device of pinholder type microneedle. Kagawa Patent WO 2011016230, 10 February 2011.
- Kis EE, Winter G., Myschik J. (2012). Devices for intradermal vaccination. Vaccine 30:523–38.
- Kochhar JS, Zou S, Chan SY, Kang L. (2012). Protein encapsulation in polymeric microneedles by photolithography. Int J Nanomed 7: 3143–54.
- Kommareddy S, Baudner BC, Bonificio A, et al. (2013). Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs. Vaccine 31:3435–41.
- Krapp KM, Longe JL. (1998). How products are made. Detroit: Gale Research.
- Koutsonanos DG, Compans RW, Skountzou L. (2013). Targeting the skin for microneedle delivery of influenza vaccine. Adv Exp Med Biol 785:121–32.
- Langkjær L, Brange J, Grodsky GM, Guy RH. (1998). Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment. J Control Release 51:47–56.
- Lanke SS, Strom JG, Banga AK. (2009). Enhancement of transdermal delivery of heparin by various physical and chemical enhancement techniques. Crit Rev Ther Drug Carrier Syst 26:581–606.
- Lawrence G. (2002). The hypodermic syringe. Lancet 359:1074.
- Lee JW, Han MR, Park JH. (2013). Polymer microneedles for transdermal drug delivery. J Drug Target 21:211–23.
- Lee K, Jung H. (2012). Drawing lithography for microneedles: a review of fundamentals and biomedical applications. Biomaterials 33:7309–26.
- Lee K, Lee CY, Jung H. (2011). Dissolving microneedles for transdermal drug administration prepared by stepwise controlled drawing of maltose. Biomaterials 32:3134e3140.

- Lee Y, Hwang K. (2002). Skin thickness of Korean adults. Surg Radiol Anat 24:183–9.
- Li H, Yu Y, Faraji DS, et al. (2013). Novel engineered systems for oral, mucosal and transdermal drug delivery. J Drug Target 21: 611–29.
- Li M, Liu Y, Wang C, et al. Inactivated vaccine for immunoprophylaxis of bovine mastitis caused by Escherichia coli and its preparation method. Raleigh Patent CN 101991846, 30 March 2011.
- Li N, Peng L-H, Chen X, et al. (2011b). Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers. Vaccine 29:6179–90.
- Lim CY. The plastic microneedle strip. Singapore Patent WO 2013066262, 10 May 2013.
- Liebl H, Kloth LC. (2012). Skin cell proliferation stimulated by microneedles. J Am Coll Clin Wound Spec 4:2–6.
- Ling MH, Chen MC. (2013). Dissolving polymer microneedle patches for rapid and efficient transdermal delivery of insulin to diabetic rats. Acta Biomater 9:8952–61.
- Magnenat-Thalmann N, Kalra P, Lévêque JL, et al. (2002). A computational skin model: fold and wrinkle formation. IEEE Trans Inf Technol Biomed 6:317–23.
- Mansoor I, Liu Y, Häfeli UO, Stoeber B. (2013). Arrays of hollow outof-plane microneedles made by metal electrodeposition onto solvent cast conductive polymer structures. J Micromech Microeng 23: 1–10.
- Martin CJ, Allender CJ, Brian KR, et al. (2012). Low temperature fabrication of Biodegradable sugar glass microneedles for transdermal drug delivery applications. J Control Release 158:93–101.
- Martanto W, Davis SP, Holiday NR, et al. (2004). Transdermal delivery of insulin using microneedles in vivo. Pharm Res 21:947–52.
- Margetts L, Sawyer R. (2007). Transdermal drug delivery: principles and opioid therapy. Cont Educ Anaesth Crit Care Pain 7:171–6.
- McAllister HS, Allen DV, Allen MG, Prausnitz MR. (1998). Microfabricated microneedles: a novel approach to transdermal drug delivery. J Pharm Sci 87:922–5.
- Milewski M, Brogden NK, Stinchcomb AL. (2010). Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin. Expert Opin Drug Deliv 7:617–29.
- Milewski M, Mitra A. (2012). Recent developments in microneedle technology for transdermal drug delivery & vaccination. Drug Dev Deliv 12:30–5.
- Mitragotri S. (2012). Mechanical disruption of skin barrier for vaccine delivery. Drug Deliv Syst 27:202–12.
- Mitragotri S. (2013). Devices for overcoming biological barriers: the use of physical forces to disrupt the barriers. Adv Drug Deliv Rev 65: 100–3.
- Mitragotri S, Kost J. (2004). Low-frequency sonophoresis: a review. Adv Drug Deliv Rev 56:589–601.
- Moga BJ, Chase KB, Smith GD. DD device. Madison Patent WO 2011084951, US 20110172645, 14 July 2011.
- Nalesniak M, Iwaniak K, Kasperek R, Poleszak E. (2013). A review of TTS-development, types and preparations. Curr Issues Pharm Med Sci 26:88–93.
- Nalwa HS. (2014). A special issue on reviews in nanomedicine, drug delivery and vaccine development. J Biomed Nanotechnol 10: 1635–40.
- Natayan RJ. (2014). Transdermal delivery of insulin via microneedles. J Biomed Nanotechnol 10:2244–60.
- Nava-Arzaluz MG, Calderón-Lojero L, Quintanar-Guerrero D, et al. (2012). Microneedles as transdermal delivery systems: combination with other enhancing strategies. Curr Drug Deliv 9:57–73.
- Nayak A, Das DB. (2013). Potential of biodegradable microneedles as a transdermal delivery vehicle for lidocaine. Biotechnol Lett 35: 1351–63.
- Nayak A, Das DB, Vladisavljevic GV. (2014). Microneedle assisted permeation of lidocaine carboxymethylcellulose with gelatine copolymer hydrogel. Pharm Res 31:1170–84.
- Nayak A, Babla H, Han T, Das DB. (in press). Lidocaine carboxymethylcellulose with gelatine co-polymer hydrogel delivery by combined microneedle and ultrasound. Drug Deliv. DOI: 10.3109/ 10717544.2014.935985. [Epub ahead of print].
- Nordquist L, Roxhed N, Griss P, Stemm G. (2007). Novel microneedle patches for active insulin delivery are efficient in maintaining glycaemic control: an initial comparison with subcutaneous administration. Pharm Res 24:1381–8.

- Norman JJ, Arya JM, McClain MA, et al. (2014). Microneedle patches: usability and acceptability for self-vaccination against influenza. Vaccine 32:1856–62.
- Olatunji O, Igwe CC, Ahmed AS, et al. (2014). Microneedles from fish scale biopolymer. Appl Polym Sci 131:1–10.
- Osborne JL, Sanchez IC, Paul DR. (2013). An asymptotic analysis of drug delivery from transdermal patches. J Memb Sci 442: 27–30.
- Pankratz A. (1983). Forecasting with Univariate Box–Jenkins Models: concepts and cases. New York: John Wiley & Sons. ISBN: 978-0-471-09023-6.
- Park JH, Allen MG, Prausnitz MR. (2005). Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J Control Release 104:51–66.
- Petrofsky JS, Prowse M, Lohman E. (2008). The influence of ageing and diabetes on skin and subcutaneous fat thickness in different regions of the body. J Appl Res 8:55–61.
- Pierre MBR, Rossetti FC. (2014). Microneedle-based drug delivery systems for transdermal route. Curr Drug Targets 15: 281–91.
- Prausnitz MR. (2004). Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 56:581–7.
- Prausnitz MR, Langer R. (2008). Transdermal drug delivery. Nat Biotechnol 26:1261–8.
- Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. (2009). Microneedle-based vaccines. Curr Top Microbiol Immunol 333: 369–93.
- Prausnitz MR, Mitragoti S, Langer R. (2004). Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 3: 115–24.
- Ravi S, Sharma PK, Bansal M. (2011). A review: transdermal drug delivery of nicotine. Int J Drug Dev Res 3:1–8.
- Rizwan M, Aqil M, Talegaonkar S, et al. (2009). Enhanced transdermal drug delivery techniques: an extensive review of patents. Recent Pat Drug Deliv Formul 3:105–24.
- Rose JE, Jarvik ME, Rose KD. (1984). Transdermal administration of nicotine. Drug Alcohol Depend 13:209–13.
- Roxhed N, Gasser TC, Griss P, et al. (2007). Penetration-enhanced ultrasharp microneedles and prediction on skin interaction for efficient transdermal drug delivery. J Microelectromech Syst 16: 1429–40.
- Sachdeva V, Banga AK. (2011). Microneedles and their applications. Recent Pat Drug Deliv Formul 5:95–132.
- Saacs E, Cobbledick T. A microneedle roller. Borehamwood Patent GB2472778A, 23 February 2011.
- Seidenari S, Pagnoni A, Di Nardo A, Giannetti A. (1994). Echographic evaluation with image analysis of normal skin: variations according to age and sex. Skin Pharmacol 7:201–9.
- Shah UU, Roberts M, Gul MO, et al. (2011). Needle-free and microneedle drug delivery in children: a case for disease-modifying antirheumatic drugs (DMARDs). Int J Pharm 416:1–11.
- Shikida M. (2012). Fabrication of microneedles by MEMS technologies. Drug Deliv Syst 27:176–83.
- Sinha VR, Kaur MP. (2000). Permeation enhancers for transdermal drug delivery. Drug Dev Ind Pharm 26:1131–40.
- Singh N, Kalluri H, Herwadkar A, et al. (2012). Transcending the skin barrier to deliver peptides and proteins using active technologies. Crit Rev Ther Drug Carrier Syst 29:265–98.
- Singh ND, Banga AK. (2013). Controlled delivery of ropinirole hydrochloride through skin using modulated iontophoresis and microneedles. J Drug Target 21:354–66.
- Singh TR, Dunne NJ, Cunningham E, Donnelly RF. (2011). Review of patents on micro needle applicators. Recent Pat Drug Deliv Formul 5: 11–23.
- Singh TR, Garland MJ, Cassidy CM, et al. (2010). Microporation techniques for enhanced delivery of therapeutic agents. Recent Pat Drug Deliv Formul 4:1–17.
- Smalls LK, Wickett RR, Visscher MO. (2006). Effect of dermal thickness, tissue composition, and body site on skin biomechanical properties. Skin Res Technol 12:43–9.
- Stinchcomb AL, Banks SL, Golinski MJ, et al. Cannabidiol prodrugs in topical and transdermal administration with microneedles. Lexington Patent WO 2011026144, S 20110052694, 3 March 2011.
- Subedi RK, Oh SY, Chun M-K, Choi H-K. (2010). Recent advances in transdermal drug delivery. Arch Pharm Res 33:339–51.

- Sugimura H, Suzuki G, Ueno M, et al. Microneedle and method of manufacturing microneedle. Tokyo Patent US 20130030374 A1, 31 January 2013.
- Sullivan SP, Murthy N, Prausnitz MR. (2008). Minimally invasive protein delivery with rapidly dissolving polymer microneedles. Adv Mater 20:933–8.
- Swain S, Beg S, Singh A, et al. (2011). Advanced techniques for penetration enhancement in transdermal drug delivery system. Curr Drug Deliv 8:456–73.
- Tanner T, Marks R. (2008). Delivering drugs by the transdermal route: review and comment. Skin Res Technol 14:249–60.
- Taylor MJ, Sahota TS. (2013). New technologies in insulin delivery. Pract Diabetes 30:21–6.
- Torrisi BM, Zarnitsyn V, Prausnitz MR, et al. (2013). Pocketed microneedles for rapid delivery of a liquid-state botulinum toxin A. J Control Release 165:146–52.
- Trommer H, Neubert RH. (2006). Overcoming the stratum corneum: the modulation of skin penetration. A review. Skin Pharmacol Physiol 19: 106–21.
- Tsioris K, Raja WK, Pritchard EM, et al. (2012). Fabrication of silk microneedles for controlled-release drug delivery. Adv Functional Mater 22:330–5.
- Tuan-Mahmood TM, McCrudden MC, Torrisi BM, et al. (2013). Microneedles for intradermal and transdermal drug delivery. Eur J Pharm Sci 50:623–37.
- Ukawala Ravikumar D, Vasava J. (2012). Physical enhancement techniques for transdermal delivery system: a review. Int J Pharm Technol 4:2174–200.
- van der Maaden K, Trietsch SJ, Kraan H, et al. (2014). Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a study with polio vaccine in rats. Pharm Res 31: 1845–54.
- Wang X, Chen X, Yu Z, Wang L. (2006). A novel fabrication approach for microneedles using silicon micromaching technology. 1st IEEE International Conference on Nano/Micro Engineered and Molecular Systems; Zhuhai.

- Wei-Ze L, Mei-Rong H, Jian-Ping Z, et al. (2010). Super-short solid silicon microneedles for transdermal drug delivery applications. Int J Pharm 389:122–9.
- Wolff HM. (2014). Future of transdermal drug delivery systems (TDDS). Am Pharm Rev 17. http://www.americanpharmaceuticalreview.com/ Featured-Articles/163672-Future-of-Transdermal-Drug-Delivery-Systems-TDDS/.
- Wu F, Yang S, Yuan W, Jin T. (2012). Challenges and strategies in developing microneedle patches for transdermal delivery of protein and peptide therapeutics. Curr Pharm Biotechnol 13:1292–8.
- Yadav JD, Vaidya KA, Kulkarni PR, Raut R. (2011). Microneedles: promising technique for transdermal drug delivery. Int J Pharma Bio Sci 2:684–708.
- Yamashita A, Hirai Y, Tojo K. (1996). Effect of ultrasound on rate of drug absorption through skin. J Chem Eng Japan 29:812–16.
- Yang Y, Kalluri H, Banga AK. (2011). Effects of chemical and physical enhancement techniques on transdermal delivery of cyanocobalamin (vitamin B12) in vitro. Pharmaceutics 3:474–84.
- Yue R, Wang Y. Metal microneedle array, transdermal patch, micro needle roller and micro needle electrode array. Beijing Patent CN 103263727, 28 August 2013.
- Zahn JD, Hsieh YC, Yang M. (2005). Components of an integrated microfluidic device for continuous glucose monitoring with responsive insulin delivery. Diabetes Technol Ther 7:536–45.
- Zhang D, Das DB, Rielly CD. (2014a). Potential of microneedle-assisted micro-particle delivery by gene guns: a review. Chem Eng Sci. DOI: 10.1016/j.ces.2014.06.031 [Epub ahead of print].
- Zhang D, Das DB, Rielly CD. (2014b). Microneedle assisted microparticle delivery by gene guns: mathematical model formulation and experimental verification. Drug Deliv. DOI: 10.3109/ 10717544.2013.864345 [Epub ahead of print].
- Zhang J, Zhu Q, Zhang L. (2013). Research advances in applications of microneedles in transdermal drug delivery. Pharma Care Res 13: 326–31.
- Zhang L, Wu Z. Riamcinolone acetonide biodegradable maltose microneedle array for treating scar and its preparation method. Shanghai Patent CN 103181887, 3 July 2013.